1. Short title This Act may be cited as the Douglas Mike Day Psychedelic Therapy to Save Lives Act of 2023 . 2. Grant program of the Department of Defense to study treatment of certain conditions using certain psychedelic substances (a) Establishment Not later than 90 days after the date of enactment of this Act, the Secretary of Defense shall award grants to eligible entities to conduct research on the treatment of members of the Armed Forces serving on active duty with a covered condition using covered psychedelic substances. Not later than 60 days after the date of the enactment of this Act, the Secretary shall designate a lead administrator to carry out the grant program under this section. (b) Eligible entities The Secretary may award a grant under this section to any of the following: (1) A department or agency of the Federal Government or a State government. (2) An academic institution. (3) A nonprofit entity. (c) Use of grant funds A recipient of a grant awarded under this section may use the grant to— (1) conduct one or more phase two clinical trials for the treatment of covered conditions that— (A) include members of the Armed Forces serving on active duty as participants in the clinical trial; and (B) use individual or group therapy assisted by covered psychedelic substances; or (2) train practitioners to provide treatment to members of the Armed Forces serving on active duty for covered conditions using covered psychedelic substances. (d) Participation in clinical trials The Secretary shall authorize any member of the Armed Forces diagnosed with a covered condition to participate in a clinical trial that is conducted using a grant awarded under this section or funds provided under subsection (e) and is authorized pursuant to section 505 of the Federal Food, Drug, and Cosmetic Act ( 21 U.S.C. 355 ), without regard to— (1) whether the clinical trial involves a substance included in the schedule under section 202 of the Controlled Substances Act ( 21 U.S.C. 812 )